关于肾缺血再灌注损伤的药物治疗研究进展  

Progress in Drug Treatment for Renal Ischemic Reperfusion Injury

作　　者：宋桂玲[1,2] 于莲[1] 胡静波[2] 杜永忠[2] 

机构地区：[1]佳木斯大学药学院,黑龙江佳木斯154007 [2]浙江大学药学院

出　　处：《中国药师》2017年第4期724-728,共5页China Pharmacist

基　　金：国家自然科学基金项目(编号:81274101)

摘　　要：肾缺血再灌注损伤是指在肾组织缺血基础上恢复血液灌注后肾脏功能不能得到恢复,并发生一系列病理生理反应。目前尚无治疗肾缺血再灌注损伤的特效药物。文章根据肾缺血再灌注损伤的病理生理特点,综合国内外最新研究结果,综述包括细胞凋亡蛋白酶抑制药、P-选择素拮抗药、抗氧化剂等治疗肾缺血再灌注损伤药物的研究进展。为肾缺血再灌注损伤的有效干预提供参考。Renal ischemia reperfusion injury refers to the recovery failure of renal function induced by renal perfusion after ischemia, and resulting in a series of pathophysiological reactions. At present, there are no sovereign drugs for the treatment of renal ischemia reperfusion injury. Based on the pathophysiological characteristics of renal ischemia reperfusion injury and the latest research results at home and abroad, the article reviewed the research progress in the therapeutical drugs for renal ischemia reperfusion injury, including apoptotie protease inhibitors, P-selectin antagonists and antioxidants, which could provide reference for the effective intervention with the disease.

关 键 词：肾缺血再灌注 细胞凋亡蛋白酶抑制药 抗氧化剂 P-选择素拮抗药 研究进展 

分 类 号：R965.1[医药卫生—药理学]